Literature DB >> 10195398

The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs.

W H Boehncke1, M Kock, K Hardt-Weinelt, M Wolter, R Kaufmann.   

Abstract

Mesh:

Substances:

Year:  1999        PMID: 10195398     DOI: 10.1007/s004030050391

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  5 in total

Review 1.  Humanized mouse models of genetic immune disorders and hematological malignancies.

Authors:  Rajeev K Tyagi; Jing Li; Justin Jacobse; Scott B Snapper; Dror S Shouval; Jeremy A Goettel
Journal:  Biochem Pharmacol       Date:  2019-10-18       Impact factor: 5.858

Review 2.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

Review 3.  [Psoriasis SCID-mouse model].

Authors:  J Pfeffer; R Kaufmann; W-H Boehncke
Journal:  Hautarzt       Date:  2006-07       Impact factor: 0.751

4.  Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model.

Authors:  Thomas M Zollner; Maurizio Podda; Christine Pien; Peter J Elliott; Roland Kaufmann; Wolf-Henning Boehncke
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

5.  Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Authors:  Smriti Kundu-Raychaudhuri; Yi-Je Chen; Heike Wulff; Siba P Raychaudhuri
Journal:  J Autoimmun       Date:  2014-08-28       Impact factor: 7.094

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.